RxDoctor Payments Data

Kristine Perle, MD

Family Medicine · Painted Post, NYNPI 1508885971

Payments from drug & device makers

$406in general payments, 2019–2025

Across 26 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$171
  • AbbVie$101
  • AstraZeneca$56
  • Novo Nordisk$37
  • Alkermes, Inc.$15
  • Boehringer Ingelheim$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$38093%
  • Education$277%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$406 in reported general payments places this provider in the 50th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$75,769
Medicare patients
310
Services billed
1,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$141,291
TrulicityDulaglutide82$125,571
JardianceEmpagliflozin73$112,330
OzempicSemaglutide51$73,939
FarxigaDapagliflozin Propanediol33$50,217
XareltoRivaroxaban36$37,715
JanuviaSitagliptin Phosphate22$35,953
Combivent RespimatIpratropium/Albuterol Sulfate21$24,856
LinzessLinaclotide17$12,757
Breo ElliptaFluticasone/Vilanterol11$11,181
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,093
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$9,964
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$9,773
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$9,341
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$9,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat$15$146,526114 claims
Lilly USA, LLCTrulicity$12$125,57182 claims
Novo NordiskOzempic$37$73,93951 claims
AstraZenecaFarxiga, Symbicort, Pulmicort Flexhaler$56$58,60464 claims
MerckJanuvia$171$35,95322 claims
AbbVieLinzess, Synthroid$101$14,61370 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,321 family medicine providers in New York.

Other family medicine in Painted Post

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →